Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab

Douglas I Lin,Julia C F Quintanilha,Natalie Danziger,Lixin Lang,Diane Levitan,Cynthia Hayne,Matthew C Hiemenz,David L Smith,Lee A Albacker,Jeffrey Leibowitz,Douglas A Mata,Brennan Decker,Sotirios Lakis,Nimesh R Patel,Ryon P Graf,Julia A Elvin,Jeffrey S Ross,Varun Pattani,Richard S P Huang,Amy K Wehn
DOI: https://doi.org/10.1038/s41698-024-00679-7
2024-09-14
Abstract:Microsatellite instability high (MSI-H) and mismatch repair deficient (dMMR) tumor status have been demonstrated to predict patient response to immunotherapies. We developed and validated a next-generation sequencing (NGS)-based companion diagnostic (CDx) to detect MSI-H solid tumors via a comprehensive genomic profiling (CGP) assay, FoundationOne®CDx (F1CDx). To determine MSI status, F1CDx calculates the fraction of unstable microsatellite loci across >2000 loci using a fraction-based (FB) analysis. Across solid tumor types, F1CDx demonstrated a high analytical concordance with both PCR (n = 264) and IHC (n = 279) with an overall percent agreement (OPA) of 97.7% and 97.8%, respectively. As part of a retrospective bridging clinical study from KEYNOTE-158 Cohort K and KEYNOTE-164, patients with MSI-H tumors as determined by F1CDx demonstrated an objective response rate (ORR) of 43.0% to pembrolizumab. In real-world cancer patients from a deidentified clinicogenomic database, F1CDx was at least equivalent in assessing clinical outcome following immunotherapy compared with MMR IHC. Demonstrated analytical and clinical performance of F1CDx led to the pan-tumor FDA approval in 2022 of F1CDx to identify MSI-H solid tumor patients for treatment with pembrolizumab. F1CDx is an accurate, reliable, and FDA-approved method for the identification of MSI-H tumors for treatment with pembrolizumab.
What problem does this paper attempt to address?